雷替曲塞联合L-OHP与5-Fu/LV联合L-OHP方案治疗晚期结直肠癌的临床疗效比较

 目的 评价雷替曲塞联合奥沙利铂（L-OHP）治疗晚期大肠癌的疗效和安全性。方法 40例晚期复治大肠癌患者分为两组,A组20例,予雷替曲塞3mg/m^2,d1,静脉注射15min,奥沙利铂130mg/m^2,d1静脉滴注3h,每3周重复1次。B组20例,奥沙利铂130mg/m^2,d1静脉滴注3h,甲酰四氢叶酸200mg/m^2,静脉滴注2h,续以5-Fu400mg/m^2静脉滴注6～8h,连用5d,每3周重复1次,每次计为1治疗周期。结果 A、B两组分别有19例和18例可评价,RR分别为36.8%和22.2%,中位TTP分别为7.8个月和5.0个月,两组结果比较差异有统计学意义（P〈0.05）。结论 雷替曲塞联合L-OHP方案在临床疗效优于5-Fu/LV联合L-OHP方案。

Comparison of Raltitrexed Plus Oxaliplatinl and 5-Fluorouracil/Leucovorin Plus Oxaliplatinl in Treatment of Advanced Colorectal Carcinoma

Objective The aim of the study was to assess the effect and security of raltitrexed with oxaliplatinl in the treatment of advanced colorectal carcinoma. Methods Forty cases of advanced colorectal cancer were divided into two groups, 20 cases in group A were given intravenously raltitrexed 15 min drip with 3 mg/ m2 on day 1, oxaliplatinl 3-hour drip with 130 mg/m2 on day 1. The regimen was repeated every 3 weeks was a cycle. 20 cases in group B were given oxaliplatinl 130 mg/m2 over 3 hours infusion on day 1, leucovorin 200 mg/ m2 infusion over 2 hours from day 1 to day 5 and 5-fluorouracil 400 mg/m2 for 4-6hours as the same way. The regimen was repeated every 3 weeks was a cycle. Evaluated the data is from the 2 groups. Results 19 and 18 patients respectively in groups A and B could be evaluated, RR were 36.8% and 22.2%,Median TTP were 7.8 and 5.0 mouths respectively(P<0.05). Conclusion The clinical efficacy of raltitrexed plus oxaliplatinl is better than 5-fluorouracil and leucovorin plus oxaliplatinl.